Search Results for:
-
Other News To Note
The drug's PDUFA date is Aug. 26BioWorld Today | Monday, May 20, 2013 -
Algeta's Xofigo Wins FDA Nod Ahead of Schedule
Algeta ASA and partner Bayer AG disclosed FDA approval Wednesday for Xofigo (radium Ra 223 dichloride) in castration-resistant prostate cancer, with the agency's nod coming three months ahead of the Aug. 14 PDUFA dateBy Catherine Shaffer | BioWorld Today | Thursday, May 16, 2013 -
Elan Buying into Theravance, GSK Royalty Stream for $1B
It has a Dec. 18 PDUFA date and is also under review in EuropeBy Cormac Sheridan | BioWorld International | Wednesday, May 15, 2013 -
Pearl's LAMA/LABA Combo Inhaler Enters Phase III Trial
Anoro Ellipta, a LAMA/LABA combo product from the collaboration between GSK and Theravance Inc. – recently approved Breo Ellipta, a combination LABA and inhaled corticosteroid, emerged from that same alliance – is currently under FDA review, with a Dec. 18 PDUFA date. (See BioWorld Today, May 13, 2013.)By Catherine Shaffer | BioWorld Today | Wednesday, May 15, 2013 -
Elan Buying into Theravance, GSK Royalty Stream for $1B
It has a Dec. 18 PDUFA date and is also under review in EuropeBy Cormac Sheridan | BioWorld Today | Tuesday, May 14, 2013 -
Other News To Note
Earlier this month, Alimera resubmitted the new drug application for Iluvien, which has a PDUFA date of Oct. 17BioWorld Today | Thursday, May 9, 2013 -
ODAC Takes AVEO to Task over Single Phase III Trial
While we are disappointed with the outcome of the ODAC vote, we remain confident in the efficacy, safety and tolerability of tivozanib in RCC patients," he said, adding that AVEO will work closely with the FDA to address the issues raised by the panel ahead of the drug's July 28 PDUFA dateBy Mari Serebrov | BioWorld Today | Friday, May 3, 2013 -
CRL on Probuphine Raises Questions on Adcom Relevance
Burrill Institutional Research analyst Elemer Piros suggested following the adcom that Probuphine's PDUFA date might be extended by three months to tweak the REMS programBy Marie Powers | BioWorld Today | Thursday, May 2, 2013 -
FDA Gives its Nod to Procysbi; Raptor Ascends
The FDA put some lift under the wings of Raptor Pharmaceutical Corp., approving the orphan drug Procysbi (RP103, cysteamine bitartrate delayed-release) on its PDUFA date in the initial indication of nephropathic cystinosis (NCBy Marie Powers | BioWorld Today | Wednesday, May 1, 2013 -
AVEO Drops on Possibility of Second Phase III Trial
Even though the market is crowded with competitors like Nexavar, Sutent (sunitinib, Pfizer Inc.), Torisel (temsirolimus, Pfizer Inc.) and Votrient (pazopanib, GlaxoSmithKline plc), AVEO hoped to clean up by positioning tivozanib as a best-in-class option. (See BioWorld Today, Feb. 17, 2011.) Looking beyond tivozanib's July 28 PDUFA date for the advanced RCC indication, AVEO is developing the drug for other cancersBy Mari Serebrov | BioWorld Today | Wednesday, May 1, 2013 -
Theravance Divides its Assets into Two Separate Businesses
The PDUFA date is May 12. (See BioWorld Today, April 18, 2013.) According to the company, Theravance Biopharma will be capitalized with approximately $300 million at separation, which is expected to fund operations through significant potential corporate milestones over two to three yearsBy Peter Winter | BioWorld Today | Tuesday, April 30, 2013 -
Theravance Jumps on Briefing Docs for GSK-Partnered Breo
Breo's PDUFA date is May 12By Jennifer Boggs | BioWorld Today | Tuesday, April 16, 2013 -
Transaction Values Dipped Significantly in First Quarter
The transaction valued the company at approximately $958 million. (See BioWorld Today, Jan. 24, 2013.) The deal provided Allergan access to MAP's Levadex, an orally inhaled formulation of the intravenous migraine drug dihydroergotamine (DHE), which is under FDA review in acute migraine with a PDUFA date of April 15By Peter Winter | BioWorld Insight | Monday, April 15, 2013 -
Investors Continue Their Love Affair with Biotech
The FDA approved the synthetic guanylate cyclase C agonist in August 2012 ahead of its PDUFA date, as a treatment for irritable bowel syndrome with constipation and for chronic constipationBy Peter Winter | BioWorld Insight | Monday, April 1, 2013 -
Committee to Scrutinize Titan's Implantable Buprenorphine
The product was granted priority review for maintenance treatment of opioid dependence in adults with a PDUFA date of April 30By Catherine Shaffer | BioWorld Today | Wednesday, March 20, 2013 -
Other News To Note
QRxPharma Ltd., of Sydney, Australia, said the FDA set a PDUFA date of Aug. 26 for the resubmitted new drug application seeking approval of Moxduo, an immediate-release dual opioid pain therapy that combines morphine and oxycodoneBioWorld International | Wednesday, March 20, 2013 -
Other News To Note
QRxPharma Ltd., of Sydney, Australia, said the FDA set a PDUFA date of Aug. 26 for the resubmitted new drug application seeking approval of Moxduo, an immediate-release dual opioid pain therapy that combines morphine and oxycodoneBioWorld Today | Friday, March 15, 2013 -
Companies Look to Capture Part of Growing Respiratory Market
and Relvar in Europe, has a PDUFA date of May 12By Peter Winter | BioWorld Insight | Monday, March 11, 2013 -
Other News To Note
The PDUFA date for the sNDA is Oct. 21BioWorld Today | Thursday, March 7, 2013 -
Panel Gives Thumbs-Down to Depomed's Hot Flash Drug
The FDA will consider the adcom's recommendation when it reviews Sefelsa, which has a May 31 PDUFA dateBy Jennifer Boggs | BioWorld Today | Tuesday, March 5, 2013
Category
Current Filters
- xPDUFA date
Related Keywords
Categories
- x BioWorld Today (580)
- x BioWorld Insight (58)
- x BioWorld International (46)
- x Bio Perspectives (32)
- x State of the Industry Report (7)
- x BioWorld Phase III Report (5)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.